News
Pharma company warns of the impacts of underinvesting in women’s health
Experts call for change, as data reveals ‘tremendous gaps’ in research and development

The US pharmaceutical company Organon has called for recognition of the impacts of underinvesting in women’s health, as only one per cent of research and innovation is dedicated to conditions unique to women.
Leading up to International Women’s Day, on March 8, Organon is challenging the healthcare ecosystem, including academia, investors, policymakers and researchers, to consider the consequences of continuing to treat women’s health as an afterthought.
Women account for more than half of the population and mothers make approximately 80 per cent of health care decisions.
Despite this, “tremendous gaps” exist in research and development efforts to advance treatment options for women, researchers have found.
According to a 2020 study, only one per cent of healthcare research and innovation is invested in conditions unique to women.
Across the Middle East, North Africa, and Turkey (MENAT) region, plenty of untapped opportunities and challenges remain.
According to a Q4 2021 analysis released by FemTech Analytics – a subsidiary of the UK-based Deep Knowledge Group – investment in healthtech in the MENA region grew by 280 per cent, but none directed at femtech.
Furthermore, MENA’s overall share of the total number of femtech companies barely reached six per cent.
Organon is providing its employees, including over 400 employees in the MENAT region, with paid time off to shine a light and speak out in service of women’s health.
“The launch of Organon in the MENAT region came with a promise to deliver a better and healthier world to women and their families,” said Ramy Koussa, associate vice president for the MENAT region at Organon.
“As a company that is focused on innovations that improve women’s health, it is pivotal for us to understand and address the needs of our over 400 employees in the region.”
He added: “The first step of advancing women’s health is listening to women to understand their needs.
“To achieve this goal, it is vital to engage all relevant stakeholders involved and committed to this cause, and we call on these stakeholders to join us in marking international women’s day with us.”
Organon says multiple research and studies across numerous areas of women’s health reveal crucial and dangerous gaps that impact nearly all stages of a woman’s lifer life.
One survey found that 83 per cent of women involved in the study felt menopause negatively affected their day-to-day life while another one estimated the prevalence of endometriosis to be 12.9 per cent in Middle Eastern women undergoing laparoscopy.
“For far too long, women’s health issues have been underfunded, under researched and underserved,” said Koussa.
“Our team have been engaged in multiple activities, panels, initiatives, and projects to support women’s health and we continue to work closely with key government stakeholders and various medical societies to educate and empower women.”
Adolescent health
Newly-launched Female Health Hub will support grassroots football players

A new Female Health Hub launched by the English FA will support women and girls in grassroots football in England with trusted advice on health issues affecting play.
The hub brings together expert-backed guidance, practical tools and player insights in one place, giving women and girls practical advice and reassurance on female health in football.
It has four core aims: to help women and girls better understand their bodies and how female health affects performance and participation, to educate players on key health topics and when to seek further advice or support, to provide practical strategies to help navigate common female health challenges, and to help break down taboos and normalise conversations around female health in football.
Users of the hub will also be able to hear directly from members of the England women’s national team, who share their own experiences of navigating female health matters while playing at the highest level of the game.
“Our ambition is to create a game where women and girls can thrive,” said Sue Day, the FA’s director of women’s football.
“To achieve that, it’s essential that players feel supported in environments that understand and respond to their female health needs.
“We’ve heard directly from grassroots players that they want better information and support around female health, but that they often don’t know where to find it.
“The launch of the Female Health Hub marks an important step in changing the landscape.
“We want every player to feel confident in her own skin and supported without judgment, so she can feel empowered by her body, rather than held back by it.”
The platform was launched following research conducted by the FA that highlighted the need for better education and support around female health in football.
According to the FA, 88 per cent of adult players surveyed said their menstrual cycle has an impact on their ability to train or play, but 86 per cent reported they had never received education about the menstrual cycle in relation to football performance and training.
The research also found 64 per cent of women experience issues related to sports bras or breast health while playing football, despite sports bras being considered one of the most important pieces of playing kit.
Players also expressed strong interest in learning more about injury prevention, at 87 per cent, nutrition, at 84 per cent, and mental health, at 77 per cent, in relation to female health.
The first phase of the Female Health Hub focuses on three of the most requested topics: menstrual health, breast health and injury resilience, with further content to follow, including nutrition and pelvic health guidance.
Pregnancy
Women’s health strategy a ‘missed opportunity,’ RCM says
Fertility
Genetic carrier screening before pregnancy: What to know

Article produced in association with London Pregnancy Clinic and Jeen Health
For the majority of couples planning a pregnancy, genetic testing is not something they think about until a problem arises.
Pre-conception genetic carrier screening challenges this approach by identifying risk before pregnancy begins.
As panel sizes have grown and at-home testing options have become widely available, carrier screening is transitioning from a niche clinical referral into a mainstream component of reproductive planning.
What Carrier Screening Tests For
Being a carrier of a genetic condition means carrying one copy of a variant in a gene associated with that condition, without being affected by it.
In most cases, carriers are entirely unaware of their status.
The clinical significance of carrier status emerges when both members of a couple carry a variant in the same gene: in this scenario, each pregnancy carries a one in four chance of resulting in a child who inherits two copies of the variant and is affected by the condition.
The conditions most frequently included in expanded carrier screening panels include cystic fibrosis, spinal muscular atrophy (SMA), fragile X syndrome, sickle cell disease, and a range of metabolic and enzyme deficiency disorders.
The Beacon 787 carrier test, offered by Jeen Health, screens for 787 conditions from a single sample, making it one of the most comprehensive panels currently available to UK families.
Who Is Most Likely to Benefit
Any couple planning a pregnancy can consider carrier screening. It is particularly relevant for:
- Couples with a family history of a known inherited condition
- Those from populations with higher carrier frequencies for specific conditions, including Ashkenazi Jewish, South Asian and African communities
- Couples pursuing fertility treatment, where genetic information informs treatment planning
- Those who wish to have the most complete picture of their reproductive health before conception
Importantly, being a carrier of a condition does not mean a child will be affected. It means there is a defined statistical risk that can be quantified, discussed and planned for with appropriate clinical support.
How the Test Is Performed
Carrier screening is typically carried out on a blood or saliva sample.
For at-home options such as the testing offered by Jeen Health, a cheek swab collection kit is dispatched to the patient, the sample is returned by post, and results are delivered digitally within a defined turnaround period.
In-clinic carrier testing may use a blood draw and provides the advantage of immediate access to a clinical consultation at the point of result delivery.
London Pregnancy Clinic offers genetics counselling through its partnership with Jeen Health, allowing couples to receive and contextualise carrier test results with expert support.
Genetic counselling before and after testing is recommended by Genomics England as a standard component of any genomic testing pathway.
What Happens If Both Partners Are Carriers
If both partners are identified as carriers for the same autosomal recessive condition, they are typically offered further counselling to discuss their options.
These may include proceeding naturally with an awareness of the risk, using prenatal diagnosis (CVS or amniocentesis) during pregnancy to test the fetus, or pursuing preimplantation genetic testing (PGT) in the context of IVF, which allows unaffected embryos to be selected before transfer.
The purpose of identifying carrier status before pregnancy is to give couples time to consider these options without the added pressure of an ongoing pregnancy.
Knowledge of carrier status does not remove reproductive choices; it expands the information available when making them.
The Role of Pre-Conception Services
Carrier screening sits within a broader category of pre-conception care that includes fertility assessments, general health optimisation and, where relevant, management of existing conditions before pregnancy begins.
London Pregnancy Clinic offers pre-conception services encompassing fertility investigations, genetics counselling and carrier testing as part of an integrated 0th trimester approach, allowing couples to address genetic and clinical risk factors before their pregnancy starts rather than after.
Disclaimer: This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment.
Clinical guidance referenced reflects published NHS, NICE and RCOG standards as at March 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article.
This piece was produced in association with London Pregnancy Clinic and Jeen Health, which provided background clinical information for editorial purposes.
Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.
Entrepreneur2 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Menopause4 weeks agoCalifornia plans US$3.4m menopause care overhaul
Hormonal health3 weeks agoWatchdog bans five ads for women’s heath claims
Pregnancy2 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
Menopause4 weeks agoMenopause has no lasting impact on cognition, research finds
Entrepreneur3 weeks agoWHIS USA 2026 announces first ticket release for landmark Women’s Health Innovation Summit
News2 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Opinion3 weeks agoQ1 momentum: Female founders are advancing, but the system still hasn’t caught up















Pingback: New fund to accelerate women-led health start-ups in Africa - FemTech World
Pingback: Women in tech ‘unequally impacted’ by the cost of living crisis and Covid -study - FemTech World
Pingback: Organon launches US$30m initiative to reduce unplanned pregnancies - FemTech World
Pingback: Israeli AI start-up raises US$12m to advance cancer drug discovery - FemTech World
Pingback: Female-led biotech start-up raises £1.27m to develop drug delivery technology for cancer therapy - FemTech World
Pingback: Ferring and BioInnovation Institute enter strategic collaboration to advance innovation in women’s health - FemTech World
Pingback: Silicon Valley VC firm closes US$460m fund to ‘fuel’ digital health innovation - FemTech World